PH26653A

PH26653A - Novel dosage form

Info

Publication number: PH26653A
Application number: PH39411A
Authority: PH
Inventors: Karin Malmqvist-Granlund; Christer Hermansson; Soren Kulstad
Original assignee: Pharmacia Ab
Priority date: 1988-10-26
Filing date: 1989-10-25
Publication date: 1992-09-04
Also published as: CN1043957C; NO894255D0; NO179478B; IL92036A; HUT52399A; IE893342L; HU201883B; FI895059A0; DK533989D0; ATE90556T1; CN1042071A; HU895452D0; KR0120111B1; PT92103A; LV10382A; LV10382B; IE62640B1; KR900005965A; ZA898127B; DK533989A

Description

Novel Dosage Form

The present invention relates to an oral pharmaceutical controlled release multiple units dosage form in which individual units containing an active sub- stance are surrounded by a coating which releases the active substance through diffusion. 1

Technical background

The term “controlled release multiple units formulation” (Bechgaard &

Hegermann Nielsen, 1978) indicates a pharmaceutical formulation comprising a multiplicity (typically at least 100) of individual coated (or “‘microencap- sulated”) units contained in the formulation in such a form that the individual units will be made available from the formulation upon disintegration of the formulation in the stomach of animals, including humans, who have ingested the formulation. Typically, the multiple units formulation may be a gelatin cap- sule or a tablet which disintegrates in the stomach to make available a multi- plicity of coated units.

Controlled release multiple units formulations aim at a controlled release of active substance in a predetermined pattern to reduce and delay the peak plasma concentration without affecting the extent of drug availability. Due to a lower peak plasma concentration, the frequency of undesirable side-effects may be reduced, and due to the delay in the time it takes to obtain the peak plasma concentration and the prolongation of the time above the thera- peutically active plasma concentration, the dosage frequency may be reduced to a dosage taken only twice or once a day, in order to improve patient com- pliance.

A further advantage of the controlled release multiple units dosage form is that high local concentration of the active substance in the gastrointestinal system is avoided, due to the units being distributed freely throughout the gastrointes- tinal tract. \

Drug release from a controlled release dosage form is generally controlied by a coating outside an active core. The release can be acchieved a) by diffusion: the coating swells in aqueous environment so that the active substance can diffuse through the stagnant liquide phase contained in the coating polymer, or b) by osmosis: the coating is semipermeable, i.e. only water can penetrate the coating polymer and dissolve the active substance, this will lead to a pressure buildup inside the coating, in order to allow the active to be released from the unit a hole or channel with a well defined area must be formed in the coating, this can be acchieved either by laser drilling (SE patent 435 8397 - US patent 4256108 to Alza) or by incorporation of a substance which will form the chan- nels by erosion after ingestion (US patent 4687 660 and European Patent Ap- plication 0171 457 to Wellcome), should the coating have any weak spots or cracks in it these will increase the release area and as a result give varying

26653 2 dissolution rates for different units, i.e. zero order release will not be achieved for the hole dose, or c) by erosion: the coating will disintegrate by a process dependent on, e.g. enzymes or pH and leave the active core exposed to rapid dissolution. The importance of a pH independent diffusion with respect to obtaining a repro- ducible rate of availability and to minimizing intra- and intersubject variations is known (GB Patent No. 1,468, 17 and bechgadrd & Baggesen, 1980). Itis also known that controlled drug release in vivo can be achieved through an erodable process by enteric coating of a multiple units dosage form (Green, 1966: McDonald et al., 1977; Bogentoft et al., 1978).

The present invention deals with multiple units dosage forms controlled by diffusion membranes. Contrary to previously known diffusion membranes used for multiple unit dosages the membrane according to the invention is non- swellable in water and gastrointestinal fluids. Furthermore the polymer used must be insoluble in and impermeable to water and pores are formed in the membrane after ingestion by a pH independent erosion process. The pores will give the coating a sponge-like apperance and will be filled with stagnant liquid where the active substance can diffuse out from the core.

Disclosure of the invention

A number of coatings employed in connection with pharmaceutical controlled ee release multiple units formulations have been observed to suffer from the " disadvantage that they change their release characteristics in the course of time. This means that it is not possible to maintain a reproducible release rate of an active substance contained in the multiple units formulation as a variable release rate has been observed for such coatings. In accordance with the present invention, it has unexpectedly been found that by selecting a special type of controlled release system which has not previously been used or dis- closed for multiple units formulations many problems connected to multiple units formulations can be avoided.

In macro scale, i.e. for tablets, controlled release systems based on coatings containing pore-creating substances has been disclosed in, e.g. the GB Patent

No. 1,186,990, the US Patent No. 3,538,214 and in the US Patent No. 4,557,925. The present release system is based on the principle of coating a core including an active substance with a film essentially consisting of a poly- mer that is insoluble in and impermeable to water and gastrointestinal fluids, and in which a watersoluble pore-creating substance is randomly distributed.

It is also required that the polymer is non-swellable in water and gastrointesti- nal fluids. When applying this controlled release system to multiple units for- mulations it was unexpectedly found that important advantages could be ob- tained.

It was thus found that it is possible to coat different types of particles, including crystals, in ordinary coating equipment, i.e. in different types of standard equipment normally available in a pharmaceutical industry. From this follows that the manufacturing process is comparatively easy and cheap. Additionally it was found that a uniform essentially zero order controlled release rate could be obtained also when relatively non-uniform particles were used as cores.

This is usually not the case in conventional multiple units controlled release formulations. For example diffusion controlled release from multiple units where the polymer swells are dependent on the thickness of the diffusion layer which will differ with time since the polymer will release the active substance while the swelling continues. This will lead to different release rates at the be- ginning and end of the release period which will result in a release more si- milar to first order release than zero order. Osii.olic conirolied £iusiple winits on the other hand are dependent on both the ability of the substances in the core to draw water into it, which may lead to lowered release rate at the end of the release period if the osmotic active and drug active substances are not the same, and the coating quality, which, if it has any weak spots or cracks in it, in- creases the release area. Such defects give varying dissolution rates for diffe- rent units, i.e. zero order release will not be achieved for the multiplicity of the units contained in a dose.

Another advantage of the present invention is the possibility of adjusting the release rate by changing the film thickness. In currently commercially used multiple unit systems this possibility seems to exist in a rather unpredictable manner and only up to a certain film thickness. In the present system, on the contrary, an essentially linear correlation exists between the release rate and the film thickness. This means that for a given type of film the release rate de- creases when the film thickness increases in a proportional manner in accor- dance with Fick's first law of diffusion.

It is also possible to change the release rate by changing the ratio between the pore-creating substance and the coating polymer. This gives the present sys- . tem a unique possibility to utilize active substances with very different solu- ~~ . bilities, which is a great advantage over the existing multiple units controlled release systems.

Thus, one aspect of the invention relates to an oral pharmaceutical controlled release multiple units formulation characterized by individual units containing an active substance, which units are provided with an outer coating consisting essentially of a polymer that is insoluble in, impermeable to and non-swellable in water and gastrointestinal fluids, and a watersoluble pore-creating sub- stance which is randomly distributed in the polymer. Another aspect of the in- vention is a formulation in which units of the type described above are com- bined with uncoated units which comprise the same or another active sub- stance for instant release thereof, and/or with non-diffusion coated units which have been provided with a coating selected from hydrophilic coatings, hydro- phobic coatings, waterbased coatings and organic coatings imparting desired properties to the unit such as acid or alkali resistance, storage stability, taste masking, light stability, colouring, improved processability, etc. The ratio be- tween diffusion coated and uncoated or non-diffusion coated units in the com- position may be adjusted according to, for instance, the desired release cha- racteristics of the composition, but is preferably in the range of about 10:90 to 90: 10 of diffusion coated units to uncoated or non-diffusion coated units.

The oral pharmaceutical controlled release multiple units formulation accord- ing to the invention will typically be a gelatin capsule containing a multiplicity of the units, typically more than 100, a sachet containing a multiplicity of the units, typically more than 500, or a tablet made from a multiplicity of the units, typically more than 100, in such a manner that the tablet will after ingestion oo (— - - : | BAD ORIGINAL Pp’

disintegrate in the stomach into a multiplicity of individual units. In each of the three above mentioned formulations the units will be freely distributed throug- out the gastrointestinal tract shortly after ingestion.

Detailed description of the invention

Coating

The coating polymer should have good filmforming and adhesive properties, and should be readily soluble in organic solvents such as acetone, methylene chlorid, methylethyl ketone or mixtures of acetone and ethanol or methylene chloride. Suitable polymers are non swelling cellulose derivates, acrylic poly- mers and vinyl polymers. Preferably the coating polymer is a polymer con- taining 80-95% weight by weight vinyl chloride, 1-19% weight by weight vinyl acetate and 0-10% weight by weight vinyl alcohol. Preferably containing 88- 94% weight by weight vinyl chloride, 2-5% weight by weight vinyl acetate and 3-5% weight by weight vinyl alcohol.

Preferably plasticizers also are present in the coating. The amount may vary between 1 to 50% weight by weight of the coating polymer, preferably be- tween 10 and 40%. Examples of suitable plasticizers are acetyltributylcitrate, polyethylene glycol, blown castor oil and glyceryl triacetate. Futhermore, the coating may include sodium bicarbonate as stabilizing agent in amounts be- tween 1 and 20% weight by weight of the coating polymer, preferably 5 to 15% weight by weight of the coating polymer.

The pore-creating substance used according to the present invention should be highly water-soluble, insoluble in the solvent used for coating, pharmaco- cologically acceptable and essentially free from own pharmacological effects in the amounts used. Especially preferred are sugars such as saccharose and lactos, and salts such as sodium chloride.

The particle size of the pore-creating substance may vary between 0.1 and 100, preferably between 0.5 and 50 pm. The ratio between the amount of pore-creating substance and coating polymer depends on the desired disso- lution rate. Generally the ratio should be between 0.05 and 5, preferably be- tween 0.1 and 2.

The coating thickness is also dependent on the desired dissolution rate. it may vary between 5 and 300 pm, preferably 10 and 150 pm.

Cores

The individual units of the multiple units formulations according to the inven- tion are coated cores consisting of crystals or pellets. The crystal units are substantially monolitic crystals. The pellets are constituted by a combination of active substance and excipients. One major type of pellets consists of an ex- cipient seed-particle with active substance applied to its surface. Typical pel lets of this type are the so-called “non-pareil” pellets where the seeds are in the form of spherical particles of saccharose. In another pellet formulation principle of this type the seeds are in the form of chrystalline saccharose.

Another major type of pellets consists of cross-sectionally substantially homo- genous particles prepared e.g. wet-granulation or extrusion.

The diameter of the cores is normally about 0.1-1.5 mm, preferably about 0.4- 1.2 mm, preferably with a range of about 0.4 mm within a specific formulation.

Active substance

The active substance in the formulations according to the invention may be any active substance which is advantageously administered in a controlled release multiple units formulations. Examples of suitable active substances are found among almost all therapeutic groups, including diuretics, antiepilep- tics, sedatives, antiarrythmics, antirheumatics, B-blockers, vasodilators, anal- gesics, bronchodilators, hormones, vitamins, oral antidiabetics, antibiotics, antihypertensives, antiinflammatory drugs, antimicrobial agents and antidepressants, polypeptides, enzymes and mucopolysaccharides.

As examples of active substances may be mentioned phenylpropanolamine, potassium chloride, quinidine salts, lithium carbonate, acetyl cystein, depyridamol, theophylline, choline theophyllinate, dextropropoxyphene, dextromethorphan, salbutamol, terbutaline, digoxin, furosemide, propranolol, ibuprofen, lidocaine, mepyramine, morphine, nitroglycerine, clonidine, diso- pyramide, verapamil, captopril, prazocin, nifedipine, diltiazem, paracetamol, . indomethacin, ticlopedine, oxybutynin and noscapine. SE

Among these substances, some are characterized as having a pH-indepen- dent solubility, others as having a pH-dependent solubility. Active substances having a pH-dependent solubility are preferably incorporated in cores in com bination with buffering substances such as sodium bicarbonate, citric acid, succinic acid or tartaric acid, in order to obtain a dissolution of active sub- stance which is substantially independent of the gastrointestinal pH variations through which the units will pass.

Method

Generally the method of producing the coated multiple unit preparation accor- ding to the invention comprises the steps of dissolving the polymer in a sol- vent, preparing a suspension of the pore-creating substance, mixing the sus- pension of pore-creating substance and the solvent solution of the polymer to form a coating fluid, prepare multiple unit cores containing an active substance in the form of crystals or pellets, applying the coating fluid to the core units, and drying the units in order to evaporate the solvent and provide polymer-coated multiple units having the water-soluble pore-creating substance randomly dis- tributed within the coating.

The solvent for the polymer can be selected from, e.g. acetone, methylene chloride, methylethyl ketone or mixtures of acetone and ethanol or methylene chloride.

The pore-creating particles are micronized either by dry milling or by wet-mil- ling to a defined particle size, preferably between 0.5 pm and 50 ym. The par-

ticles are dispersed in solvents such as those previously mentioned, and mixed with the terpolymer solution.

The coating fluid may, as previously stated, include a plasticizer and sodium bicarbonate.

Coloring matter can also be incorporated in the coating fluid, and insoluble ’ coloring materials are preferred.

The coating fluid, in the form of a suspension, is then applied on drug-con- taining cores. A special advantageous feature is that the coating process can be performed in ordinary coating equipment, i.e. in different types of standard equipment normally available in a pharmaceutical industry. This is due to the good filmforming and adhesive properties of the coating material, and the easiness of solvent evaporation from the system. Examples of such coating equipments are pan coating in sugar-coating pans or perforated film-coating pans, Wiirster coating, and other fluid-bed coating procedures. From this fol- lows that the manufacturing process is comparatively easy and cheap.

The following examples further illustrate the invention but should not be con- strued as limiting to the invention.

Example 1

Theophylline is a weak acid (pKa = 8.7) which is poorly soluble in water. The . cores used in this example contain 60% theophylline on non-parils and have a particle size of 0.8 - 1.0 mm. These cores (1.0 kg) are coated with a coating suspension of the following composition:

Terpolymer containing 92% vinylchloride, 4% vinylacetate and 4% vinylalcohol weight by weight 390g

Micronized succrose (particle size 1-10 pm) 930g

Acetyl tributyl citrate 89g

Blown castor oil 68g

Sodium bicarbonate 34g

Aceton ad 10.000g

The coating suspension is applied on the cores with an airless spray-coating device in a coating pan. Samples are taken after the application of 1.0, 2.0 and 3.0 kg of the suspension.

Table 1 shows the dissolution rate of a dose corresponding to 90 mg theo- phylline. The dissolution testing is performed according to the USP XXI basket method (100 rpm). There is a linear correlation between the release rate and the coating thickness, and the release rate is essentially independent of the pH. A uniform zero order release rate is observed during the major part of the release time.

. JTable 1

Time Released amount of theophyliine (%) (hours) 0.2 M TRIS buffer pH 7.4 0.1 M HCI - A B Cc C 1 46 18 10 11 2 84 39 24 28 3 98 58 37 44 4 100 76 49 59 90 62 73 6 96 73 86 7 99 83 94 8 90 99 9 94 100 96 101 11 97 101 12 98 102

A: 2.5 mg coating material per cm? of the cores

B: 59" ~ . orn

C: 90" - nnn

Example 2

Choline theophylline is a salt of theophylline readily soluble in water. The cores used in this example contain 30% choline theophyllinate on sugar crys- tals and have a particle size of 0.7 - 1.0 mm. These cores (1.0 kg) are coated with a suspension of the following compositions:

Terpolymer containing 92% vinyichloride, 4% vinylacetate and 4% vinylalcohol | : weight by weight 295g

Micronized succrose (particle size 1-10 pm) 930 g

Acetyl tributyl citrate 30g ~ Blown castor oil 23g

Sodium bicarbonate 34g . + Titanium dioxide CL 59g :

Aceton ad 10.000 g

The coating suspension is applied on the cores with an airless spray-coating device in a coating pan. Samples are taken after the application of 2.0, 2.5, 3.0 kg of the suspension.

Table 2 shows the dissolution rate of a dose corresponding to 90 mg theo- phylline. The dissolution rate testing according to the USP XXI basket method (100 rpm). The dissolution rate is considerably higher than in Example 1 due to the much higher solubility of the choline salt of theophylline than of pure theophylline. Despite the higher dissolution rate there is still a linear correla- tion between the release rate and the coating thickness.

Table 2 :

Time Released amount of theophylline (%) (hours) 0.2 M TRIS buffer pH 7.4

A B C

0.33 96 86 76 0.67 100 99 08 1.00 100 100

A: 3.7 mg coating material per cm? of the cores

B: 46° - orn

C: 55° ” orn

Example 3

Diltiazem hydrochloride is an ammonium salt readily soluble in water. The cores used in this example contain 44% diltiazem hydrochloride or non-pareils and have a particle size of 0.7 - 1.1 mm. These cores (0.9 kg) are coated with a coating suspension of the following composition:

Terpolymer containing 92% vinylchloride, 4% vinylacetate and 4% vinylalcohol weight by weight 409 g

Micronized succrose (particle size 1-10 um) 930 g

Acetyl tributyl citrate 70g ~~ Blown castor oil | 52g,

Sodium bicarbonate 34g ~~. Aceton ad 10.000 g :

The coating suspension is applied on the cores with an airless spray-coating device in a coating pan. Samples are taken after the application of 1.6, 2.3 and 3.0 kg of the suspension.

Table 3 shows the dissolution rate of a doze corresponding to 120 mg dil- tiazem hydrochloride. The dissolution testing is performed according to the

USP XXI basket method (100 rpm). The solubility of this ammonium salt is si- : milar to that of the salt in Example 2. The dissolution rate is therefore also si milar. Also here is the linear correlation between the release rate and the : coating thickness obvious.

Table 3

Time Released amount of diltiazem hydrochloride (%) (hours) 0.05 M phosphate buffer pH 7.4

A B C

0.25 48 34 27 0.50 79 67 56 0.75 91 85 80 1.00 96 91 85 1.25 98 94 91 1.50 99 97 94 1.75 100 98 96 2.00 101 99 97

A: 6.8 mg coating material per cm? of the cores

B: 98° ° - on nr

C: 124" ° " orn"

Claims

. dee Ce Se wees eS AMRSRRE ee te oa corbin BN 10 Claims

1. Oral pharmaceutical multiple units formulation comprising individual cores containing a pharmacological active substance, said cores being provided with a coating consisting essentially of a polymer, that is in- soluble in, impermeable to and non-swellable in water and gastrointes- tinal fluids, and a watersoluble pore-creating substance, which is ran- domly distributed in said polymer, whereby said coated cores form units providing an essentially zero order diffusion controlled release rate of said active substance.

2. Formulation according to claim 1 characterized in that the polymer is selected from the group comprising cellulose derivatives, acrylic poly- mers and vinyl polymers.

3. Formulation according to claim 1 or 2 characterized in that the polymer consists of a mixture of vinyl chloride, vinyl acetate and optionally vinyl alcohol. Preferably the coating polymer is a polymer containing 80-95% weight by weight vinyl chloride, 1-19% weight by weight vinyl acetate and 0-10% weight by weight vinyl alcohol.

4. Formulation according to claim 3 characterized in that the polymer is a terpolymer containing 88-94% weight by weight vinyl chloride, 2-5 weight by weight vinyl acetate and 3-5% weight by weight vinyl alcohol.

5. Formulation according to any of the claims 1-4 characterized in that the pore-creating substance is selected from the group consisting of sugars and salts.

6. Formulation according to any of the preceeding claims characterized in that it also comprises uncoated cores containing the same or another active substance for the instant release thereof.

7. Formulation according to any of the claims 1-6 characterized in that it also includes non-diffusion coated cores provided with a coating selec- ted from hydrophilic, hydrophobic, waterbased or organic coatings. -

8. Method of preparing an oral pharmaceutical multiple units formulation comprising individual cores containing a pharmacological active sub- stance, said cores being provided with a coating consisting essentially of a polymer, that is insoluble in, impermeable to and non- swellable in water and gastrointestinal fluids, and a watersoluble pore-creating sub- stance, which is randomly distributed in said polymer, whereby said coated cores form units providing an essentially zero order diffusion controlled release rate of said active substance, said method compris- ing the steps of dissolving the polymer in a solvent, preparinga suspension of the pore-creating substance, mixing the suspension of pore-creating substance and the solvent solution of the polymer to form a coating fluid, prepare multiple unit cores containing an active sub- stance in the form of crystals or pellets, applying the coating fluid to the core units, and drying the units in order to evaporate the solvent and provide polymer-coated multiple units having the water-soluble pore- creating substance randomly distributed within the coating.

9. Method according to claim 8 characterized in that the polymer is selec- ted from the group comprising cellulose derivatives, acrylic polymers and vinyl polymers.

10. Method according claim 8 characterized in that the polymer is a ter- polymer containing 88-94% weight by weight vinyl chloride, 2-5 weight by weight vinyl acetate and 3-5% weight by weight vinyl alcohol.

11. Method according to any of the claims 8-10 characterized in that the pore-creating substance is selected from the group consisting of sugars and salts. ei CL . . . . B Li ) CL Lo on -

Abstract The invention relates to an oral pharmaceutical multiple units formulation comprising individual cores containing a pharmacologically active substance, said cores being provided with a coating consisting essentially of a polymer,

. that is insoluble in, impermeable to and non-soluble in water and in gastroin- testinal fluids, and a watersoluble pore-creating substance, which is randomly distributed in said polymer, whereby said coated cores form units providing an essential zero order diffusion controlled release rate of said active substance. The invention also comprises a method of preparing these formulations.